Showing 5421-5430 of 7686 results for "".
- Emerging Technologies, Consumer Preferences Drive Microdermabrasion Market Expansionhttps://practicaldermatology.com/news/emerging-technologies-and-consumer-preferences-drive-microdermabrasion-market-expansion/2466901/A new market report indicates that microdermabrasion devices are increasingly favored in the treatment of conditions like acne, acne scars, fine lines, and wrinkles, and that the market for these devices is poised for growth. The growth, according to the report from Coherent Market Insig
- Dapsone Gel Shows Promise for Treating Acne in Skin of Colorhttps://practicaldermatology.com/news/dapsone-gel-shows-promise-treating-acne-skin-color/2463234/A new study in the Journal of Drugs in Dermatology indicates that dapsone gel, 7.5% (Aczone®, Almirall) was safe and effective in the treatment of acne vulgaris in patients with skin of color. "Acne vulgaris is a common skin disease prevalent in skin of color patients
- Survey Shows Low Awareness, High Risk of Actinic Keratosis from Sun Exposurehttps://practicaldermatology.com/news/survey-shows-low-awareness-high-risk-actinic-keratosis-sun-exposure/2463197/A recent survey conducted by Almirall showed gaps in public awareness about actinic keratosis (AK) and the associated risks of sun exposure. The survey, which included more than 2,500 participants aged 35 and older from Spain, Germany, Italy, the United Kingdom, and the United States, rev
- J&J Expands Atopic Dermatitis Pipeline with Yellow Jersey Therapeutics Acquisitionhttps://practicaldermatology.com/news/jj-expands-ad-pipeline-yellow-jersey-therapeutics-125-billion-acquisition/2463207/Johnson & Johnson (J&J) has announced its plan to acquire Yellow Jersey Therapeutics (a subsidiary of Numab Therapeutics) for $1.25 billion in cash, according to a news release. The acquisition includes the bispecific antibody NM26, which is currently advancing to phase 2 studies f
- Alma Unveils Versatile Aesthetic Workstation and Smart Skin Analysis Systemhttps://practicaldermatology.com/news/alma-unveils-versatile-aesthetic-workstation-and-smart-skin-analysis-system/2463172/Energy-based device manufacturer Alma has introduced Alma Harmony and Alma IQ. Alma Harmony is the latest version of the company's multi-technology aesthetics workstation and is available for sale in the U.S. This system, according to a press release, builds on a 20-year legacy and is FDA
- Benign Nail Condition Linked to Cancer Riskhttps://practicaldermatology.com/news/benign-nail-condition-linked-cancer-risk/2463171/The presence of a benign nail abnormality may lead to the diagnosis of a rare inherited disorder that increases the risk of developing cancerous tumors of the skin, eyes, kidneys and the tissue that lines the chest and abdomen (eg, the mesothelium), according to scientists at the National Institu
- World Congress for Hair Research Convenes in Texashttps://practicaldermatology.com/news/world-congress-hair-research-convenes-texas/2463139/Hundreds of internationally renowned scientists and clinicians interested in hair research gathered in Dallas, Texas, from April 6-9, for the 13th World Congress for Hair Research. Hosted by the American Hair Research Society (AHRS), a member of the International Federation of Hair Res
- Humira Biosimilar Simlandi Now Available in the UShttps://practicaldermatology.com/news/humira-biosimilar-simlandi-now-available-us/2463126/Teva Pharmaceuticals and Alvotech announced the availability of Simlandi (adalimumab-ryvk) injection in the US as an interchangeable biosimilar to Humira. Simlandi is indicated for the treatment of adult plaque psoriasis and adult hidradenitis suppurativa, as well as adult rheumatoid arthritis, j
- Analysis: Scar Reduction Seen with Fractional CO2 and 5-FU Laser Treatmentshttps://practicaldermatology.com/news/analysis-scar-reduction-seen-fractional-co2-and-5-fu-laser-treatments/2463110/Results from a new meta-analysis suggest that fractional carbon dioxide (FCO2) plus 5-fluorouracil (5-FU) laser therapy was effective in treating hypertrophic and keloid scars. Researchers for the analysis included data from 18 studies (N = 550). The team comprehensively search
- Survey Shows Variability in Hyaluronidase Use Among Practitionershttps://practicaldermatology.com/news/survey-shows-variability-hyaluronidase-use-among-practitioners/2463109/New research suggests there are inconsistencies in the use of hyaluronidase (HYAL) for the treatment of adverse events with hyaluronic acid (HA) fillers, suggesting a need for standardized guidelines. "With the growing popularity and administration of HA fillers, there is likely to be a c